Details of the Drug

General Information of Drug (ID: DMEO794)

• Drug Name: Galantamine
• Synonyms: GNT; Galantamin; Galantamina; Galantaminum; Galanthamine; Galanthaminum; Jilkon; Lycoremin; Lycoremine; Reminyl; Razadyne ER; Galantamina [INN-Spanish]; Galantamine [USAN:INN]; Galantaminum [INN-Latin]; Nivalin (TN); Razadyne (TN); Razadyne ER (TN); Reminyl (TN); Galantamine (USAN/INN); (-)-Galanthamine; (4aS,6R,8aS)-4a,5,9,10,11,12-Hexahydro-3-methoxy-11-methyl-6H-benzofuro(3a,3,2-ef)(2)benzazepin-6-ol

Indication

Disease Entry	ICD 11	Status	REF
Alzheimer disease	8A20	Approved	[1]
Traumatic brain injury	NA07.Z	Approved	[2]

• Therapeutic Class: Parasympathomimetics
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 0:
  Molecular Weight (mw); 287.35
  Logarithm of the Partition Coefficient (xlogp); 1.8
  Rotatable Bond Count (rotbonds); 1
  Hydrogen Bond Donor Count (hbonddonor); 1
  Hydrogen Bond Acceptor Count (hbondacc); 4
• ADMET Property:
  Absorption Tmax: The time to maximum plasma concentration (Tmax) is 2.3 h [3]
  BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [4]
  Bioavailability: The bioavailability of drug is 40.5 % [3]
  Clearance: The renal clearance of drug is 65 mL/min [5]
  Elimination: Renal clearance accounts for about 20C25% of total plasma clearance of the drug in healthy individuals: the elimination of galantamine has been shown to be decreased in subjects with renal impairment [6]
  Half-life: The concentration or amount of drug in body reduced by one-half in 7 hours [7]
  Metabolism: The drug is metabolized via the CYP2D6 and CYP3A4 [5]
  MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 1.44821 micromolar/kg/day [8]
  Unbound Fraction: The unbound fraction of drug in plasma is 0.83% [9]
  Vd: The volume of distribution (Vd) of drug is 175 L [7]
  Water Solubility: The ability of drug to dissolve in water is measured as 10 mg/mL [4]
• Chemical Identifiers:
  Formula: C17H21NO3
  IUPAC Name: (1S,12S,14R)-9-methoxy-4-methyl-11-oxa-4-azatetracyclo[8.6.1.01,12.06,17]heptadeca-6(17),7,9,15-tetraen-14-ol
  Canonical SMILES: CN1CC[C@@]23C=C[C@@H](C[C@@H]2OC4=C(C=CC(=C34)C1)OC)O
  InChI: InChI=1S/C17H21NO3/c1-18-8-7-17-6-5-12(19)9-14(17)21-16-13(20-2)4-3-11(10-18)15(16)17/h3-6,12,14,19H,7-10H2,1-2H3/t12-,14-,17-/m0/s1
  InChIKey: ASUTZQLVASHGKV-JDFRZJQESA-N
• Cross-matching ID:
  PubChem CID: 9651
  ChEBI ID: CHEBI:42944
  CAS Number: 357-70-0
  DrugBank ID: DB00674
  TTD ID: D0R9VR
  INTEDE ID: DR0761
  ACDINA ID: D00297
• Repurposed Drugs (RPD): Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Acetylcholinesterase (AChE)	TT1RS9F	ACES_HUMAN	Inhibitor	[10]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4) Main DME	DE4LYSA	CP3A4_HUMAN	Substrate	[11]
Cytochrome P450 2D6 (CYP2D6) Main DME	DECB0K3	CP2D6_HUMAN	Substrate	[11]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Acetylcholinesterase (ACHE)	OT2H8HG6	ACES_HUMAN	Gene/Protein Processing	[12]
Cholinesterase (BCHE)	OTOH3WQ9	CHLE_HUMAN	Gene/Protein Processing	[13]
Cocaine esterase (CES2)	OTC647SQ	EST2_HUMAN	Gene/Protein Processing	[14]
Neuronal acetylcholine receptor subunit alpha-4 (CHRNA4)	OT1H0ZXC	ACHA4_HUMAN	Protein Interaction/Cellular Processes	[15]
Neuronal acetylcholine receptor subunit beta-2 (CHRNB2)	OTNAT2M5	ACHB2_HUMAN	Protein Interaction/Cellular Processes	[15]

Molecular Expression Atlas of This Drug

• The Studied Disease: Alzheimer disease
• ICD Disease Classification: 8A20

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Acetylcholinesterase (AChE)	DTT	ACHE	6.39E-02	-1.07	-1.15
Cytochrome P450 2D6 (CYP2D6)	DME	CYP2D6	8.70E-01	2.98E-02	1.22E-01
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	1.76E-01	1.26E-01	8.27E-01

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Galantamine

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Donepezil	DMIYG7Z	Moderate	Additive cholinergic effects by the combination of Galantamine and Donepezil.	Alzheimer disease [8A20]	[16]

Coadministration of a Drug Treating the Disease Different from Galantamine (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Bethanechol	DMCLHO0	Moderate	Additive cholinergic effects by the combination of Galantamine and Bethanechol.	Abnormal micturition [MF50]	[16]
Midostaurin	DMI6E0R	Moderate	Increased risk of ventricular arrhythmias by the combination of Galantamine and Midostaurin.	Acute myeloid leukaemia [2A60]	[17]
Idarubicin	DMM0XGL	Moderate	Increased risk of ventricular arrhythmias by the combination of Galantamine and Idarubicin.	Acute myeloid leukaemia [2A60]	[17]
Daunorubicin	DMQUSBT	Moderate	Increased risk of ventricular arrhythmias by the combination of Galantamine and Daunorubicin.	Acute myeloid leukaemia [2A60]	[17]
Oliceridine	DM6MDCF	Moderate	Increased risk of ventricular arrhythmias by the combination of Galantamine and Oliceridine.	Acute pain [MG31]	[17]
Scopolamine	DMOM8AL	Moderate	Antagonize the effect of Galantamine when combined with Scopolamine.	Addictive disorder [6C50-6C5Z]	[18]
Mepyramine	DMB4SFH	Moderate	Antagonize the effect of Galantamine when combined with Mepyramine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[19]
Phenyltoloxamine	DMKAEQW	Moderate	Antagonize the effect of Galantamine when combined with Phenyltoloxamine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[19]
Tripelennamine	DMZBU15	Moderate	Antagonize the effect of Galantamine when combined with Tripelennamine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[18]
Metronidazole	DMTIVEN	Moderate	Increased risk of ventricular arrhythmias by the combination of Galantamine and Metronidazole.	Amoebiasis [1A36]	[17]
Bedaquiline	DM3906J	Moderate	Increased risk of ventricular arrhythmias by the combination of Galantamine and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[17]
Cilostazol	DMZMSCT	Moderate	Increased risk of ventricular arrhythmias by the combination of Galantamine and Cilostazol.	Arterial occlusive disease [BD40]	[17]
Posaconazole	DMUL5EW	Moderate	Decreased metabolism of Galantamine caused by Posaconazole mediated inhibition of CYP450 enzyme.	Aspergillosis [1F20]	[20]
Terbutaline	DMD4381	Moderate	Increased risk of ventricular arrhythmias by the combination of Galantamine and Terbutaline.	Asthma [CA23]	[17]
Salbutamol	DMN9CWF	Moderate	Increased risk of ventricular arrhythmias by the combination of Galantamine and Salbutamol.	Asthma [CA23]	[21]
Lisdexamfetamine	DM6W8V5	Moderate	Increased risk of prolong QT interval by the combination of Galantamine and Lisdexamfetamine.	Attention deficit hyperactivity disorder [6A05]	[22]
Desipramine	DMT2FDC	Moderate	Antagonize the effect of Galantamine when combined with Desipramine.	Attention deficit hyperactivity disorder [6A05]	[18]
Ofloxacin	DM0VQN3	Moderate	Increased risk of ventricular arrhythmias by the combination of Galantamine and Ofloxacin.	Bacterial infection [1A00-1C4Z]	[17]
Clarithromycin	DM4M1SG	Moderate	Decreased metabolism of Galantamine caused by Clarithromycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[20]
Sparfloxacin	DMB4HCT	Moderate	Increased risk of ventricular arrhythmias by the combination of Galantamine and Sparfloxacin.	Bacterial infection [1A00-1C4Z]	[17]
Gemifloxacin	DMHT34O	Moderate	Increased risk of ventricular arrhythmias by the combination of Galantamine and Gemifloxacin.	Bacterial infection [1A00-1C4Z]	[17]
Norfloxacin	DMIZ6W2	Moderate	Increased risk of ventricular arrhythmias by the combination of Galantamine and Norfloxacin.	Bacterial infection [1A00-1C4Z]	[17]
Levofloxacin	DMS60RB	Moderate	Increased risk of ventricular arrhythmias by the combination of Galantamine and Levofloxacin.	Bacterial infection [1A00-1C4Z]	[17]
Lomefloxacin	DMVRH9C	Moderate	Increased risk of ventricular arrhythmias by the combination of Galantamine and Lomefloxacin.	Bacterial infection [1A00-1C4Z]	[17]
Retigabine	DMGNYIH	Moderate	Increased risk of ventricular arrhythmias by the combination of Galantamine and Retigabine.	Behcet disease [4A62]	[17]
Lomustine	DMMWSUL	Moderate	Decreased metabolism of Galantamine caused by Lomustine mediated inhibition of CYP450 enzyme.	Brain cancer [2A00]	[20]
Eribulin	DM1DX4Q	Moderate	Increased risk of ventricular arrhythmias by the combination of Galantamine and Eribulin.	Breast cancer [2C60-2C6Y]	[17]
Lapatinib	DM3BH1Y	Moderate	Decreased metabolism of Galantamine caused by Lapatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[23]
Tucatinib	DMBESUA	Moderate	Decreased metabolism of Galantamine caused by Tucatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[20]
Tamoxifen	DMLB0EZ	Moderate	Increased risk of ventricular arrhythmias by the combination of Galantamine and Tamoxifen.	Breast cancer [2C60-2C6Y]	[17]
Bosutinib	DMTI8YE	Moderate	Increased risk of ventricular arrhythmias by the combination of Galantamine and Bosutinib.	Breast cancer [2C60-2C6Y]	[17]
PF-04449913	DMSB068	Moderate	Increased risk of ventricular arrhythmias by the combination of Galantamine and PF-04449913.	Chronic myelomonocytic leukaemia [2A40]	[17]
Olodaterol	DM62B78	Moderate	Increased risk of ventricular arrhythmias by the combination of Galantamine and Olodaterol.	Chronic obstructive pulmonary disease [CA22]	[17]
Halothane	DM80OZ5	Moderate	Increased risk of ventricular arrhythmias by the combination of Galantamine and Halothane.	Corneal disease [9A76-9A78]	[17]
Propofol	DMB4OLE	Moderate	Increased risk of prolong QT interval by the combination of Galantamine and Propofol.	Corneal disease [9A76-9A78]	[24]
Sevoflurane	DMC9O43	Moderate	Increased risk of ventricular arrhythmias by the combination of Galantamine and Sevoflurane.	Corneal disease [9A76-9A78]	[17]
Probucol	DMVZQ2M	Moderate	Increased risk of ventricular arrhythmias by the combination of Galantamine and Probucol.	Coronary atherosclerosis [BA80]	[17]
Clofazimine	DMEBOFW	Moderate	Increased risk of ventricular arrhythmias by the combination of Galantamine and Clofazimine.	Crohn disease [DD70]	[17]
Mifepristone	DMGZQEF	Moderate	Decreased metabolism of Galantamine caused by Mifepristone mediated inhibition of CYP450 enzyme.	Cushing syndrome [5A70]	[21]
Pasireotide	DMHM7JS	Moderate	Increased risk of ventricular arrhythmias by the combination of Galantamine and Pasireotide.	Cushing syndrome [5A70]	[17]
Sertraline	DM0FB1J	Moderate	Increased risk of ventricular arrhythmias by the combination of Galantamine and Sertraline.	Depression [6A70-6A7Z]	[17]
Trimipramine	DM1SC8M	Moderate	Antagonize the effect of Galantamine when combined with Trimipramine.	Depression [6A70-6A7Z]	[18]
Cyclobenzaprine	DM1YBRM	Moderate	Antagonize the effect of Galantamine when combined with Cyclobenzaprine.	Depression [6A70-6A7Z]	[18]
Nefazodone	DM4ZS8M	Moderate	Decreased metabolism of Galantamine caused by Nefazodone mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[20]
Paroxetine	DM5PVQE	Moderate	Decreased metabolism of Galantamine caused by Paroxetine mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[20]
Escitalopram	DMFK9HG	Moderate	Decreased metabolism of Galantamine caused by Escitalopram mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[20]
OPC-34712	DMHG57U	Moderate	Antagonize the effect of Galantamine when combined with OPC-34712.	Depression [6A70-6A7Z]	[18]
Clomipramine	DMINRKW	Moderate	Antagonize the effect of Galantamine when combined with Clomipramine.	Depression [6A70-6A7Z]	[18]
Doxepin	DMPI98T	Moderate	Antagonize the effect of Galantamine when combined with Doxepin.	Depression [6A70-6A7Z]	[19]
Maprotiline	DMPWB7T	Moderate	Antagonize the effect of Galantamine when combined with Maprotiline.	Depression [6A70-6A7Z]	[18]
Mepenzolate	DM8YU2F	Moderate	Antagonize the effect of Galantamine when combined with Mepenzolate.	Digestive system disease [DE2Z]	[18]
Oxybutynine	DMJPBAX	Moderate	Antagonize the effect of Galantamine when combined with Oxybutynine.	Discovery agent [N.A.]	[18]
Tetrabenazine	DMYWQ0O	Moderate	Increased risk of ventricular arrhythmias by the combination of Galantamine and Tetrabenazine.	Dissociative neurological symptom disorder [6B60]	[17]
Meclizine	DMS7T13	Moderate	Antagonize the effect of Galantamine when combined with Meclizine.	Dizziness and giddiness [MB48]	[18]
Deutetrabenazine	DMUPFLI	Moderate	Increased risk of ventricular arrhythmias by the combination of Galantamine and Deutetrabenazine.	Dystonic disorder [8A02]	[17]
Ingrezza	DMVPLNC	Moderate	Increased risk of ventricular arrhythmias by the combination of Galantamine and Ingrezza.	Dystonic disorder [8A02]	[17]
Rufinamide	DMWE60C	Moderate	Increased metabolism of Galantamine caused by Rufinamide mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[22]
Diphenhydramine	DMKQTBA	Moderate	Antagonize the effect of Galantamine when combined with Diphenhydramine.	Episodic vestibular syndrome [AB31]	[18]
Tropicamide	DM1D90W	Moderate	Antagonize the effect of Galantamine when combined with Tropicamide.	Eye anterior segment structural developmental anomaly [LA11]	[25]
Solifenacin	DMG592Q	Moderate	Antagonize the effect of Galantamine when combined with Solifenacin.	Functional bladder disorder [GC50]	[18]
Mirabegron	DMS1GYT	Moderate	Decreased metabolism of Galantamine caused by Mirabegron mediated inhibition of CYP450 enzyme.	Functional bladder disorder [GC50]	[26]
Tolterodine	DMSHPW8	Moderate	Antagonize the effect of Galantamine when combined with Tolterodine.	Functional bladder disorder [GC50]	[18]
Itraconazole	DMCR1MV	Moderate	Decreased metabolism of Galantamine caused by Itraconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[20]
Pentamidine	DMHZJCG	Moderate	Increased risk of ventricular arrhythmias by the combination of Galantamine and Pentamidine.	Fungal infection [1F29-1F2F]	[17]
Terbinafine	DMI6HUW	Moderate	Decreased metabolism of Galantamine caused by Terbinafine mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[27]
Ketoconazole	DMPZI3Q	Moderate	Decreased metabolism of Galantamine caused by Ketoconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[20]
Propantheline	DM2EN6G	Moderate	Antagonize the effect of Galantamine when combined with Propantheline.	Gastric ulcer [DA60]	[18]
Sunitinib	DMCBJSR	Moderate	Increased risk of ventricular arrhythmias by the combination of Galantamine and Sunitinib.	Gastrointestinal stromal tumour [2B5B]	[17]
Cyclopentolate	DMA8LM5	Moderate	Antagonize the effect of Galantamine when combined with Cyclopentolate.	General examination [QA00]	[25]
Boceprevir	DMBSHMF	Moderate	Decreased metabolism of Galantamine caused by Boceprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[20]
Telaprevir	DMMRV29	Moderate	Decreased metabolism of Galantamine caused by Telaprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[20]
Rifapentine	DMCHV4I	Moderate	Increased metabolism of Galantamine caused by Rifapentine mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[28]
Delavirdine	DM3NF5G	Moderate	Decreased metabolism of Galantamine caused by Delavirdine mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[20]
Fosamprenavir	DM4W9B3	Moderate	Decreased metabolism of Galantamine caused by Fosamprenavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[20]
Fostemsavir	DM50ILT	Moderate	Increased risk of ventricular arrhythmias by the combination of Galantamine and Fostemsavir.	Human immunodeficiency virus disease [1C60-1C62]	[17]
Cobicistat	DM6L4H2	Moderate	Decreased metabolism of Galantamine caused by Cobicistat mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[20]
Rilpivirine	DMJ0QOW	Moderate	Increased risk of ventricular arrhythmias by the combination of Galantamine and Rilpivirine.	Human immunodeficiency virus disease [1C60-1C62]	[17]
Darunavir	DMN3GCH	Moderate	Decreased metabolism of Galantamine caused by Darunavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[29]
Conivaptan	DM1V329	Moderate	Decreased metabolism of Galantamine caused by Conivaptan mediated inhibition of CYP450 enzyme.	Hypo-osmolality/hyponatraemia [5C72]	[20]
Belladonna	DM2RBWK	Moderate	Antagonize the effect of Galantamine when combined with Belladonna.	Infectious gastroenteritis/colitis [1A40]	[18]
Propiomazine	DMKY8V1	Moderate	Antagonize the effect of Galantamine when combined with Propiomazine.	Insomnia [7A00-7A0Z]	[18]
ITI-007	DMUQ1DO	Moderate	Antagonize the effect of Galantamine when combined with ITI-007.	Insomnia [7A00-7A0Z]	[18]
Polyethylene glycol	DM4I1JP	Moderate	Increased risk of lowers seizure threshold by the combination of Galantamine and Polyethylene glycol.	Irritable bowel syndrome [DD91]	[30]
Clidinium	DMUMQZ0	Moderate	Antagonize the effect of Galantamine when combined with Clidinium.	Irritable bowel syndrome [DD91]	[18]
Physostigmine	DM2N0TO	Moderate	Additive cholinergic effects by the combination of Galantamine and Physostigmine.	Lips/oral mucosa miscellaneous disorder [DA02]	[16]
Glycerol phenylbutyrate	DMDGRQO	Moderate	Decreased metabolism of Galantamine caused by Glycerol phenylbutyrate mediated inhibition of CYP450 enzyme.	Liver disease [DB90-DB9Z]	[22]
PF-06463922	DMKM7EW	Moderate	Increased metabolism of Galantamine caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[31]
Dacomitinib	DMOH8VY	Moderate	Decreased metabolism of Galantamine caused by Dacomitinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[32]
Osimertinib	DMRJLAT	Moderate	Increased risk of ventricular arrhythmias by the combination of Galantamine and Osimertinib.	Lung cancer [2C25]	[17]
Selpercatinib	DMZR15V	Moderate	Increased risk of ventricular arrhythmias by the combination of Galantamine and Selpercatinib.	Lung cancer [2C25]	[17]
Lumefantrine	DM29GAD	Moderate	Decreased metabolism of Galantamine caused by Lumefantrine mediated inhibition of CYP450 enzyme.	Malaria [1F40-1F45]	[21]
Halofantrine	DMOMK1V	Moderate	Increased risk of ventricular arrhythmias by the combination of Galantamine and Halofantrine.	Malaria [1F40-1F45]	[17]
Hydroxychloroquine	DMSIVND	Moderate	Increased risk of ventricular arrhythmias by the combination of Galantamine and Hydroxychloroquine.	Malaria [1F40-1F45]	[17]
Primaquine	DMWQ16I	Moderate	Decreased metabolism of Galantamine caused by Primaquine mediated inhibition of CYP450 enzyme.	Malaria [1F40-1F45]	[20]
Inotuzumab ozogamicin	DMAC130	Moderate	Increased risk of ventricular arrhythmias by the combination of Galantamine and Inotuzumab ozogamicin.	Malignant haematopoietic neoplasm [2B33]	[17]
Idelalisib	DM602WT	Moderate	Decreased metabolism of Galantamine caused by Idelalisib mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[20]
Arsenic trioxide	DM61TA4	Moderate	Increased risk of ventricular arrhythmias by the combination of Galantamine and Arsenic trioxide.	Mature B-cell lymphoma [2A85]	[17]
Vemurafenib	DM62UG5	Moderate	Decreased metabolism of Galantamine caused by Vemurafenib mediated inhibition of CYP450 enzyme.	Melanoma [2C30]	[33]
LGX818	DMNQXV8	Moderate	Increased risk of prolong QT interval by the combination of Galantamine and LGX818.	Melanoma [2C30]	[34]
Exjade	DMHPRWG	Moderate	Decreased metabolism of Galantamine caused by Exjade mediated inhibition of CYP450 enzyme.	Mineral absorption/transport disorder [5C64]	[35]
Panobinostat	DM58WKG	Moderate	Decreased metabolism of Galantamine caused by Panobinostat mediated inhibition of CYP450 enzyme.	Multiple myeloma [2A83]	[36]
Thalidomide	DM70BU5	Moderate	Increased risk of ventricular arrhythmias by the combination of Galantamine and Thalidomide.	Multiple myeloma [2A83]	[21]
Siponimod	DM2R86O	Major	Increased risk of atrioventricular block by the combination of Galantamine and Siponimod.	Multiple sclerosis [8A40]	[21]
Fingolimod	DM5JVAN	Moderate	Increased risk of atrioventricular block by the combination of Galantamine and Fingolimod.	Multiple sclerosis [8A40]	[37]
Ozanimod	DMT6AM2	Major	Increased risk of ventricular arrhythmias by the combination of Galantamine and Ozanimod.	Multiple sclerosis [8A40]	[38]
Neostigmine	DM6T2J3	Moderate	Additive cholinergic effects by the combination of Galantamine and Neostigmine.	Myasthenia gravis [8C6Y]	[16]
Edrophonium	DMCRQHB	Moderate	Additive cholinergic effects by the combination of Galantamine and Edrophonium.	Myasthenia gravis [8C6Y]	[16]
Ambenonium	DMOP0BL	Moderate	Additive cholinergic effects by the combination of Galantamine and Ambenonium.	Myasthenia gravis [8C6Y]	[16]
Romidepsin	DMT5GNL	Moderate	Increased risk of ventricular arrhythmias by the combination of Galantamine and Romidepsin.	Mycosis fungoides [2B01]	[17]
Fedratinib	DM4ZBK6	Moderate	Decreased metabolism of Galantamine caused by Fedratinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[22]
Nilotinib	DM7HXWT	Moderate	Decreased metabolism of Galantamine caused by Nilotinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[39]
Dasatinib	DMJV2EK	Moderate	Decreased metabolism of Galantamine caused by Dasatinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[40]
Phenindamine	DMDTC7R	Moderate	Antagonize the effect of Galantamine when combined with Phenindamine.	Nasopharyngitis [CA00]	[18]
Promethazine	DM6I5GR	Moderate	Antagonize the effect of Galantamine when combined with Promethazine.	Nausea/vomiting [MD90]	[18]
Rolapitant	DM8XP26	Moderate	Decreased metabolism of Galantamine caused by Rolapitant mediated inhibition of CYP450 enzyme.	Nausea/vomiting [MD90]	[41]
Cyclizine	DM9G7BS	Moderate	Antagonize the effect of Galantamine when combined with Cyclizine.	Nausea/vomiting [MD90]	[18]
Granisetron	DMIUW25	Moderate	Increased risk of ventricular arrhythmias by the combination of Galantamine and Granisetron.	Nausea/vomiting [MD90]	[17]
Dolasetron	DMMG26Z	Moderate	Increased risk of ventricular arrhythmias by the combination of Galantamine and Dolasetron.	Nausea/vomiting [MD90]	[17]
Ondansetron	DMOTQ1I	Moderate	Increased risk of ventricular arrhythmias by the combination of Galantamine and Ondansetron.	Nausea/vomiting [MD90]	[17]
Bupropion	DM5PCS7	Major	Decreased metabolism of Galantamine caused by Bupropion mediated inhibition of CYP450 enzyme.	Nicotine use disorder [6C4A]	[17]
Entrectinib	DMMPTLH	Moderate	Increased risk of ventricular arrhythmias by the combination of Galantamine and Entrectinib.	Non-small cell lung cancer [2C25]	[17]
Lorcaserin	DMG6OYJ	Moderate	Decreased metabolism of Galantamine caused by Lorcaserin mediated inhibition of CYP450 enzyme.	Obesity [5B80-5B81]	[42]
Levomethadyl Acetate	DM06HG5	Moderate	Increased risk of ventricular arrhythmias by the combination of Galantamine and Levomethadyl Acetate.	Opioid use disorder [6C43]	[21]
Lofexidine	DM1WXA6	Moderate	Increased risk of ventricular arrhythmias by the combination of Galantamine and Lofexidine.	Opioid use disorder [6C43]	[17]
Rucaparib	DM9PVX8	Moderate	Increased risk of ventricular arrhythmias by the combination of Galantamine and Rucaparib.	Ovarian cancer [2C73]	[17]
Flavoxate	DMKV4NL	Moderate	Antagonize the effect of Galantamine when combined with Flavoxate.	Pain [MG30-MG3Z]	[18]
Buprenorphine	DMPRI8G	Moderate	Increased risk of ventricular arrhythmias by the combination of Galantamine and Buprenorphine.	Pain [MG30-MG3Z]	[17]
Triclabendazole	DMPWGBR	Moderate	Increased risk of ventricular arrhythmias by the combination of Galantamine and Triclabendazole.	Parasitic worm infestation [1F90]	[17]
Biperiden	DME78OA	Moderate	Antagonize the effect of Galantamine when combined with Biperiden.	Parkinsonism [8A00]	[18]
Pimavanserin	DMR7IVC	Moderate	Increased risk of ventricular arrhythmias by the combination of Galantamine and Pimavanserin.	Parkinsonism [8A00]	[17]
Orphenadrine	DMW542E	Moderate	Antagonize the effect of Galantamine when combined with Orphenadrine.	Parkinsonism [8A00]	[18]
Apomorphine	DMX38HQ	Moderate	Increased risk of ventricular arrhythmias by the combination of Galantamine and Apomorphine.	Parkinsonism [8A00]	[17]
Ranitidine	DM0GUSX	Moderate	Antagonize the effect of Galantamine when combined with Ranitidine.	Peptic ulcer [DA61]	[18]
Methylscopolamine	DM5VWOB	Moderate	Antagonize the effect of Galantamine when combined with Methylscopolamine.	Peptic ulcer [DA61]	[18]
Famotidine	DMRL3AB	Moderate	Increased risk of ventricular arrhythmias by the combination of Galantamine and Famotidine.	Peptic ulcer [DA61]	[17]
Macimorelin	DMQYJIR	Moderate	Increased risk of ventricular arrhythmias by the combination of Galantamine and Macimorelin.	Pituitary gland disorder [5A60-5A61]	[17]
Lefamulin	DME6G97	Moderate	Increased risk of ventricular arrhythmias by the combination of Galantamine and Lefamulin.	Pneumonia [CA40]	[17]
Lonafarnib	DMGM2Z6	Moderate	Decreased metabolism of Galantamine caused by Lonafarnib mediated inhibition of CYP450 enzyme.	Premature ageing appearance [LD2B]	[20]
Degarelix	DM3O8QY	Moderate	Increased risk of ventricular arrhythmias by the combination of Galantamine and Degarelix.	Prostate cancer [2C82]	[17]
Relugolix	DMK7IWL	Moderate	Increased risk of ventricular arrhythmias by the combination of Galantamine and Relugolix.	Prostate cancer [2C82]	[17]
Levomepromazine	DMIKFEL	Moderate	Antagonize the effect of Galantamine when combined with Levomepromazine.	Psychotic disorder [6A20-6A25]	[18]
Temsirolimus	DMS104F	Moderate	Increased plasma concentrations of Galantamine and Temsirolimus due to competitive inhibition of the same metabolic pathway.	Renal cell carcinoma [2C90]	[43]
Gatifloxacin	DMSL679	Moderate	Increased risk of ventricular arrhythmias by the combination of Galantamine and Gatifloxacin.	Respiratory infection [CA07-CA4Z]	[17]
Oxamniquine	DM2QDX1	Moderate	Decreased metabolism of Galantamine caused by Oxamniquine mediated inhibition of CYP450 enzyme.	Schistosomiasis [1F86]	[20]
Mesoridazine	DM2ZGAN	Moderate	Antagonize the effect of Galantamine when combined with Mesoridazine.	Schizophrenia [6A20]	[18]
Aripiprazole	DM3NUMH	Moderate	Antagonize the effect of Galantamine when combined with Aripiprazole.	Schizophrenia [6A20]	[18]
Iloperidone	DM6AUFY	Moderate	Increased risk of ventricular arrhythmias by the combination of Galantamine and Iloperidone.	Schizophrenia [6A20]	[17]
Paliperidone	DM7NPJS	Moderate	Increased risk of ventricular arrhythmias by the combination of Galantamine and Paliperidone.	Schizophrenia [6A20]	[17]
Perphenazine	DMA4MRX	Moderate	Antagonize the effect of Galantamine when combined with Perphenazine.	Schizophrenia [6A20]	[18]
Molindone	DMAH70G	Moderate	Antagonize the effect of Galantamine when combined with Molindone.	Schizophrenia [6A20]	[18]
Thiothixene	DMDINC4	Moderate	Antagonize the effect of Galantamine when combined with Thiothixene.	Schizophrenia [6A20]	[18]
Trifluoperazine	DMKBYWI	Moderate	Antagonize the effect of Galantamine when combined with Trifluoperazine.	Schizophrenia [6A20]	[18]
Risperidone	DMN6DXL	Moderate	Antagonize the effect of Galantamine when combined with Risperidone.	Schizophrenia [6A20]	[18]
Asenapine	DMSQZE2	Moderate	Increased risk of ventricular arrhythmias by the combination of Galantamine and Asenapine.	Schizophrenia [6A20]	[17]
Pimozide	DMW83TP	Moderate	Antagonize the effect of Galantamine when combined with Pimozide.	Schizophrenia [6A20]	[18]
Vardenafil	DMTBGW8	Moderate	Increased risk of ventricular arrhythmias by the combination of Galantamine and Vardenafil.	Sexual dysfunction [HA00-HA01]	[17]
Vandetanib	DMRICNP	Moderate	Increased risk of ventricular arrhythmias by the combination of Galantamine and Vandetanib.	Solid tumour/cancer [2A00-2F9Z]	[17]
Triptorelin	DMTK4LS	Moderate	Increased risk of ventricular arrhythmias by the combination of Galantamine and Triptorelin.	Solid tumour/cancer [2A00-2F9Z]	[17]
Doxorubicin	DMVP5YE	Moderate	Increased risk of ventricular arrhythmias by the combination of Galantamine and Doxorubicin.	Solid tumour/cancer [2A00-2F9Z]	[17]
Pitolisant	DM8RFNJ	Moderate	Increased risk of ventricular arrhythmias by the combination of Galantamine and Pitolisant.	Somnolence [MG42]	[17]
Telavancin	DM58VQX	Moderate	Increased risk of ventricular arrhythmias by the combination of Galantamine and Telavancin.	Staphylococcal/streptococcal disease [1B5Y]	[17]
Fostamatinib	DM6AUHV	Moderate	Decreased metabolism of Galantamine caused by Fostamatinib mediated inhibition of CYP450 enzyme.	Thrombocytopenia [3B64]	[44]
Lenvatinib	DMB1IU4	Moderate	Increased risk of ventricular arrhythmias by the combination of Galantamine and Lenvatinib.	Thyroid cancer [2D10]	[17]
Cabozantinib	DMIYDT4	Moderate	Increased risk of ventricular arrhythmias by the combination of Galantamine and Cabozantinib.	Thyroid cancer [2D10]	[17]
Tizanidine	DMR2IQ4	Moderate	Increased risk of ventricular arrhythmias by the combination of Galantamine and Tizanidine.	Tonus and reflex abnormality [MB47]	[17]
Sirolimus	DMGW1ID	Moderate	Increased plasma concentrations of Galantamine and Sirolimus due to competitive inhibition of the same metabolic pathway.	Transplant rejection [NE84]	[43]
Tacrolimus	DMZ7XNQ	Moderate	Increased plasma concentrations of Galantamine and Tacrolimus due to competitive inhibition of the same metabolic pathway.	Transplant rejection [NE84]	[43]
Methdilazine	DMAUHQX	Moderate	Antagonize the effect of Galantamine when combined with Methdilazine.	Vasomotor/allergic rhinitis [CA08]	[18]
Carbinoxamine	DMCT31R	Moderate	Antagonize the effect of Galantamine when combined with Carbinoxamine.	Vasomotor/allergic rhinitis [CA08]	[18]
Trimeprazine	DMEMV9D	Moderate	Antagonize the effect of Galantamine when combined with Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[19]
Brompheniramine	DMFOVSD	Moderate	Antagonize the effect of Galantamine when combined with Brompheniramine.	Vasomotor/allergic rhinitis [CA08]	[18]
Acrivastine	DMTIGA0	Moderate	Antagonize the effect of Galantamine when combined with Acrivastine.	Vasomotor/allergic rhinitis [CA08]	[18]
Azatadine	DMZ80SB	Moderate	Antagonize the effect of Galantamine when combined with Azatadine.	Vasomotor/allergic rhinitis [CA08]	[18]
Procainamide	DMNMXR8	Moderate	Antagonize the effect of Galantamine when combined with Procainamide.	Ventricular tachyarrhythmia [BC71]	[18]
Propafenone	DMPIBJK	Moderate	Decreased metabolism of Galantamine caused by Propafenone mediated inhibition of CYP450 enzyme.	Ventricular tachyarrhythmia [BC71]	[20]
Flecainide	DMSQDLE	Moderate	Increased risk of ventricular arrhythmias by the combination of Galantamine and Flecainide.	Ventricular tachyarrhythmia [BC71]	[17]

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Allura red AC dye	E00338	33258	Colorant
D&C red no. 27	E00381	83511	Colorant
D&C red no. 30	E00456	3000709	Colorant
Diethyl phthalate	E00135	6781	Plasticizing agent; Solvent
FD&C blue no. 1	E00263	19700	Colorant
FD&C blue no. 2	E00446	2723854	Colorant
Mannitol	E00103	6251	Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Quinoline yellow WS	E00309	24671	Colorant
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sodium stearyl fumarate	E00545	23665634	lubricant
Sunset yellow FCF	E00255	17730	Colorant
Ammonia	E00007	222	Alkalizing agent
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Crospovidone	E00626	Not Available	Disintegrant
Dibutyl sebacate	E00160	7986	Plasticizing agent
Eisenoxyd	E00585	56841934	Colorant
Ferric hydroxide oxide yellow	E00539	23320441	Colorant
Ferrosoferric oxide	E00231	14789	Colorant
Hydroxypropyl cellulose	E00632	Not Available	Binding agent; Coating agent; Emulsifying agent; Film/Membrane-forming agent; Modified-release agent; Suspending agent; Viscosity-controlling agent
Hypromellose	E00634	Not Available	Coating agent
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Polyethylene glycol 400	E00653	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 80	E00665	Not Available	Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Potassium hydroxide	E00233	14797	Alkalizing agent
Propylene glycol	E00040	1030	Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Saccharose	E00091	5988	Binding agent; Coating agent; Cryoprotectant; Diluent; Flavoring agent; Suspending agent; Viscosity-controlling agent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Triacetin	E00080	5541	Humectant; Plasticizing agent; Solvent
Triethyl citrate	E00128	6506	Plasticizing agent; Solvent

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Galantamine 16 mg capsule	16 mg	24 HR Extended Release Oral Capsule	Oral
Galantamine 24 mg capsule	24 mg	24 HR Extended Release Oral Capsule	Oral
Galantamine 8 mg capsule	8 mg	24 HR Extended Release Oral Capsule	Oral
Galantamine 12 mg tablet	12 mg	Oral Tablet	Oral
Galantamine 4 mg tablet	4 mg	Oral Tablet	Oral
Galantamine 8 mg tablet	8 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6693).
• [2] Galantamine FDA Label
• [3] Mictoryl monograph
• [4] BDDCS applied to over 900 drugs
• [5] Vickers AE, Zollinger M, Dannecker R, Tynes R, Heitz F, Fischer V: In vitro metabolism of tegaserod in human liver and intestine: assessment of drug interactions. Drug Metab Dispos. 2001 Oct;29(10):1269-76.
• [6] Lilienfeld S: Galantamine--a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer's disease. CNS Drug Rev. 2002 Summer;8(2):159-76.
• [7] FDA Approved Drug Products: RAZADYNE (galantamine hydrobromide), for oral use
• [8] Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
• [9] Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
• [10] [From symptomatic to disease modifying therapy Recent developments in the pharmacotherapy of Alzheimer's disease]. Fortschr Neurol Psychiatr. 2009 Jun;77(6):326-33.
• [11] Clinical pharmacokinetics of galantamine. Clin Pharmacokinet. 2003;42(15):1383-92.
• [12] Potencies and selectivities of inhibitors of acetylcholinesterase and its molecular forms in normal and Alzheimer's disease brain. Acta Biol Hung. 2003;54(2):183-9. doi: 10.1556/ABiol.54.2003.2.7.
• [13] Lichens of parmelioid clade as promising multitarget neuroprotective agents. Chem Res Toxicol. 2019 Jun 17;32(6):1165-1177.
• [14] Inhibition of human carboxylesterases hCE1 and hiCE by cholinesterase inhibitors. Chem Biol Interact. 2013 Mar 25;203(1):226-30.
• [15] Cholinergic drugs potentiate human nicotinic alpha4beta2 acetylcholine receptors by a competitive mechanism. Eur J Pharmacol. 2005 Feb 21;509(2-3):97-108. doi: 10.1016/j.ejphar.2004.12.037.
• [16] Product Information. Aricept (donepezil). Pfizer US Pharmaceuticals, New York, NY.
• [17] Canadian Pharmacists Association.
• [18] Beers MH, Ouslander JG, Rollingher I, Reuben DB, Brooks J, Beck JC "Explicit criteria for determining inappropriate medication use in nursing home residents." Arch Intern Med 151 (1991): 1825-32. [PMID: 1888249]
• [19] Carnahan RM, Lund BC, Perry PJ, Chrischilles EA "The concurrent use of anticholinergics and cholinesterase inhibitors: rare event or common practice?" J Am Geriatr Soc 52 (2004): 2082-7. [PMID: 15571547]
• [20] Product Information. Reminyl (galantamine) Janssen Pharmaceuticals, Titusville, NJ.
• [21] Cerner Multum, Inc. "Australian Product Information.".
• [22] Cerner Multum, Inc. "UK Summary of Product Characteristics.".
• [23] Product Information. Tykerb (lapatinib). Novartis Pharmaceuticals, East Hanover, NJ.
• [24] Hanci V, Aydin M, Yurtlu BS, et.al "Anesthesia induction with sevoflurane and propofol: evaluation of P-wave dispersion, QT and corrected QT intervals." Kaohsiung J Med Sci 26 (2010): 470-7. [PMID: 20837343]
• [25] Katz IR, Sands LP, Bilker W, DiFilippo S, Boyce A, D'Angelo K "Identification of medications that cause cognitive impairment in older people: the case of oxybutynin chloride." J Am Geriatr Soc 46 (1998): 8-13. [PMID: 9434659]
• [26] Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
• [27] AbdelRahman SM, Gotschall RR, Kauffman RE, Leeder JS, Kearns GL "Investigation of terbinafine as a CYP2D6 inhibitor in vivo." Clin Pharmacol Ther 65 (1999): 465-72. [PMID: 10340911]
• [28] Product Information. Priftin (rifapentine). Hoechst Marion-Roussel Inc, Kansas City, MO.
• [29] Product Information. Prezista (darunavir). Ortho Biotech Inc, Bridgewater, NJ.
• [30] Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates). Braintree Laboratories, Braintree, MA.
• [31] Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
• [32] Product Information. Vizimpro (dacomitinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
• [33] Product Information. Zelboraf (vemurafenib). Genentech, South San Francisco, CA.
• [34] Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
• [35] Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
• [36] Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
• [37] Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
• [38] Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
• [39] Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
• [40] Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
• [41] Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
• [42] Product Information. Belviq (lorcaserin). Eisai Inc, Teaneck, NJ.
• [43] Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
• [44] Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.